Unilife Corporation, a US-based developer and commercial supplier of injectable drug-delivery systems, has signed a 15-year agreement with Hikma Pharmaceuticals, in which Unilife will supply customized prefilled syringes to Hikma for a range of generic injectable drugs.
Hikma has selected an initial list of 20 generic injectable products to be formulated using Unilife’s proprietary platform (branded as Unifill) of prefilled syringes with automatic and fully integrated needle retraction.
Under the terms of the agreement, Hikma holds exclusive global rights to its generic products using Unilife’s Unifill platform. Additional injectable drugs may also be added to the exclusivity list subject to agreement by both parties.
In return, Unilife will receive $40 million in upfront and milestone payments. An initial upfront payment of $5 million will be paid to Unilife immediately, with an additional $15 million in payments expected during 2014. The final $20 million in milestone-based payments will be paid the following year.
Unilife will start supplying the products to Hikma in early 2014, with a minimum supply volume expected to exceed 175 million units per year.